Haya Therapeutics, a biotech developing precision RNA‑guided genome therapies, has relocated its San Diego operations to Lilly Gateway Labs, a shared innovation hub run by Eli Lilly and Alexandria Real Estate Equities, according to the company.
The company said that the site will house advanced multi‑modal functional genomics labs integral to its Regulatory Genome Atlas platform and support business and clinical work, including advancement of its lead long non‑coding RNA therapy, HTX‑001, targeting heart failure.
The company claims that access to Lilly Gateway Labs’ infrastructure and biotech ecosystem will accelerate development of its RNA‑guided therapeutics platform designed to reprogram disease‑driving cell states for rare, chronic and age‑related diseases.
This move follows a $65 million Series A financing co‑led by Sofinnova Partners and Earlybird Venture Capital, with participation from Lilly and Alexandria Venture Investments.
The company said that Haya will remain fully independent and retain all assets and intellectual property while operating at Lilly Gateway Labs.
This relocation reflects growing momentum in RNA‑guided and regulatory genome‑targeting biotech, as Haya expands facility capacity to accelerate progress toward its lead clinical candidate.
